Government funding to enable Phase II respiratory infection programme
Drug Discovery World
SEPTEMBER 5, 2023
The new funding will support the non-clinical toxicology and safety studies needed to enable a seasonal prophylaxis Phase IIb study to demonstrate the safety, tolerability, and efficacy of intranasal INNA-051 in preventing respiratory illness in people aged 65 or older. “Early studies validated the safety of INNA-051 and provided proof of pharmacology (..)
Let's personalize your content